ORKA vs PEN
Oruka Therapeutics, Inc. vs Penumbra, Inc. — AI-powered side-by-side comparison
ORKA
Oruka Therapeutics, Inc.
59
Watch
VS
PEN
Penumbra, Inc.
67
Buy
| Metric | ORKA | PEN |
|---|
| AI Score |
59
|
67
|
| Price |
$104.56
|
$326.07
|
| P/E Ratio |
-43.80×
|
79.78×
|
| ROE |
-22.3%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
67.8%
|
| Debt / Equity |
0.00×
|
0.14×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
74.0
|
79.6
|
| Beta |
-0.389
|
0.701
|
| Expected Upside |
—
|
+6.3%
|
AI Committee View
Current Innellis committee reasoning for ORKA versus PEN.
PEN leads by 8 points.
PEN scores 67/100 (Buy) versus ORKA at 59/100 (Watch).
ORKA Committee View
60% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -26.0% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical